A Better Treatment Option for Drug-Resistant Tuberculosis

Lowering the linezolid dose in a bedaquiline-pretomanid-linezolid regimen provided comparable efficacy with less toxicity.

Safe, effective treatment options are urgently needed for those with tuberculosis caused by drug-resistant Mycobacterium tuberculosis. In a recent study in South Africa, the combination of bedaquiline, pretomanid, and linezolid (1200 mg linezolid daily; BPL 1200) for 26 weeks yielded a microbiologic cure rate over 90%, but with significant linezolid toxicity (NEJM JW Infect Dis May 2020 and N Engl J Med 2020 Mar 5; 382:893). Now, these investigators have assessed the efficacy and toxicity of four different 26-week regimens for highly drug-resistant pulmonary tuberculosis in which linezolid was given at 1200 mg daily for 9 weeks (BPL 1200-9) or 26 weeks (BPL 1200-26), or at 600 mg daily for 9 weeks (BPL 600-9) or 26 weeks (BPL 600-26).

Among …

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

A Better Treatment Option for Drug-Resistant Tuberculosis

Topics

Reviewing Author